Navigation Links
Medimetriks Pharmaceuticals Launches Company's First Prescription Brands

Medimetriks introduces 3 new therapies for the Dermatology and Podiatry Markets

FAIRFIELD, N.J., Jan. 12 /PRNewswire/ -- Medimetriks Pharmaceuticals, Inc. announced today that the Company launched its first prescription topical therapies into the Dermatology and Podiatry markets. The three new brands are Pacnex(TM) (7% Benzoyl Peroxide) Wash, a topical treatment for acne; Sumaxin(TM) (Sodium Sulfacetamide 10% & Sulfur 4%) Cleansing Pads, a topical treatment for acne, rosacea and seborrheic dermatitis; and Uramaxin(TM) (45% Urea) Nail Gel, a treatment for diseased and damaged nails.

A unique attribute of these therapies is the addition of natural ingredients. The vehicles for Pacnex(TM) Wash and Sumaxin(TM) Cleansing Pads both contain Green Tea and Aloe, natural ingredients gaining wide acceptance. Green Tea is known for its antioxidant properties and Aloe for its natural soothing benefits. Sumaxin(TM) Cleansing Pads also have the unique attribute of a reduced sulfur odor, addressing a common complaint with sulfur-based topical therapies. Uramaxin(TM) Nail Gel offers a vehicle containing Menthol, Camphor and Eucalyptus Oil, ingredients designed to naturally mask the odor often associated with diseased nails.

"Since the launch of our company eight months ago, Medimetriks' staff has leveraged its expertise to create and bring to market high quality topical therapies that offer elegant formulations, provide value to patients, and enhance patient care," stated Bradley Glassman, President and CEO of Medimetriks. "These brands were developed with the objective of meeting the therapeutic needs of both physicians and their patients, and we believe we have developed three brands that meet that objective."

Medimetriks' new field force is strategically located in the most significant markets in which the new brands compete. "Physicians are now seeing Medimetriks Sales Representatives in their offices," said Mr. Glassman. "These sales professionals are highly trained and charged with the mission of championing patient care through the ethical promotion of skincare therapy, delivering knowledge, service and value to our core physician audiences and their patients."

With the launch of these brands into the Dermatology and Podiatry markets, Medimetriks will begin to establish a leadership role in supporting the Dermatology and Podiatry communities. The Company will actively support the organizations critical to these specialties and provide education important to their patients.

Medimetriks is planning for the launch of additional topical prescription therapies in the first quarter of 2009.

Important Product Safety Information:

Pacnex(TM) Wash is for external use only. Avoid contact with eyes, lips or mucous membranes. If severe irritation develops, discontinue use of Pacnex(TM) Wash. While using Pacnex(TM) Wash, patients should be advised to avoid unnecessary sun exposure. Please see full Prescribing Information available at

Sumaxin(TM) Cleansing Pads are contraindicated in persons with known or suspected hypersensitivity to sulfonamides or sulfur. Sumaxin(TM) Cleansing Pads are not to be used by patients with kidney disease. Although rare, topical sodium sulfacetamide may cause local irritation. Please see full Prescribing Information available at

Uramaxin(TM) Nail Gel is for external use only. Avoid contact with eyes, lips or mucous membranes. Transient stinging, burning, itching or irritation may occur and normally disappear on discontinuing the medication. Use as directed. Please see full Prescribing Information available at

About Medimetriks Pharmaceuticals, Inc.

Medimetriks Pharmaceuticals, Inc. develops, licenses and commercializes prescription skincare products primarily for the Dermatology and Podiatry marketplaces. The Company's mission is to enhance patient quality-of-life by providing innovative therapies that advance patient care.

The Company is located at 363 Route 46 West, Fairfield, NJ 07004-2402. Please visit the Medimetriks website at, call (973) 882-7512 or fax (973) 882-7502.

SOURCE Medimetriks Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Perrigo Company Licenses Prescription Brands to Medimetriks Pharmaceuticals
2. Wyeth Pharmaceuticals and Santaris Pharma Announce Strategic Alliance to Develop RNA-based Medicines
3. Warner Chilcott and Watson Pharmaceuticals Announce Agreements on Loestrin(R) 24 and Femcon(R) Fe Patent Litigation
4. Celator(R) Pharmaceuticals To Present at Biotech Showcase 2009
5. Amira Pharmaceuticals, Inc. Expands its Scientific Advisory Board and Appoints Dr. Paul Anderson, Professor Jerold Chun and Professor Andrew Tager
6. Prism Pharmaceuticals to Receive $10 Million Milestone Payment from Paul Capital Healthcare
7. Poniard Pharmaceuticals Provides 2009 Clinical Data Goals for Picoplatin
8. Isis Pharmaceuticals to Present at the J.P. Morgan Healthcare Conference
9. Cell Therapeutics Receives $7.5 Million Under Joint Venture Agreement With Spectrum Pharmaceuticals
10. MiddleBrook Pharmaceuticals to Launch Moxatag(TM) March 2009
11. Amylin Pharmaceuticals to Present at JPMorgan Healthcare Conference
Post Your Comments:
(Date:12/1/2015)... ... December 01, 2015 , ... On Tuesday 27 Oct 2015, ... educate the personnel on spinal decompression therapy and offer his professional help. , ... The benefits come from creating negative intradiscal pressure which is conducive to retraction ...
(Date:12/1/2015)... ... 01, 2015 , ... World Patent Marketing , a vertically integrated ... allows for easier packing and organizing of items into one big, portable jar. , ... Cooper, CEO and Creative Director of World Patent Marketing and Desa Industries Inc ...
(Date:12/1/2015)... ME (PRWEB) , ... December 01, 2015 , ... Royal ... reports a new study that found post-menopausal women who took the nutritional supplement creatine, ... than women who trained but did not take creatine. , The report is part ...
(Date:12/1/2015)... ... December 01, 2015 , ... According to an article ... a discrimination claim against the U.S. Department of Health and Human Services, claiming that ... (ACA) plans are breaking the clause in the law prohibiting the denial of coverage ...
(Date:12/1/2015)... Los Angeles, CA (PRWEB) , ... December 01, 2015 , ... ... the United States, today announced that its iconic bottle has won top honors in ... drinks category. The Company also announced that it has been selected as a ...
Breaking Medicine News(10 mins):
(Date:12/1/2015)... and PITTSBURGH , Dec. ... announced that it expects to be the first to ... funded by international donors, TLE400 (Tenofovir Disoproxyl Fumarate 300 ... for $99 per patient, per year. Mylan partnered with ... The significantly reduced price could generate savings of tens ...
(Date:12/1/2015)...  Six months of adjunctive metformin therapy does not improve ... to new research from T1D Exchange and funded ... beneficial effect on measures of obesity, including weight and BMI. ... Journal of the American Medical Association , are from the ... on overweight and obese adolescents with type 1 diabetes. ...
(Date:12/1/2015)... 01, 2015 ... addition of the "2016 Europe ... E. Coli, Enterovirus, Rhinovirus, Rotavirus, Salmonella, ... their offering. --> ... the "2016 Europe Enteric Disease ...
Breaking Medicine Technology: